Hepatitis B surface antigen (HBsAg) variants

Viral Hepatitis

Volumn , Issue , 2007, Pages 225-241

  Carman, William F ^a   Jazayeri, Mohammad ^a   Basuni, Ashraf ^a   Thomas, Howard C ^b   Karayiannis, Peter ^c  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Active immunization; Amino acid level; Geographical variability; Hepatitis B surface antigen; Passive immunization

Indexed keywords

EID: 35348911521     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987131.ch14     Document Type: Chapter

References (121)

1. Neurath AR, Kent SBH. Antigenic structure of human hepatitis viruses. In: van Regenmortel MVH, Neurath AR, eds. Immunohistochemistry of Viruses. Amsterdam: Elsevier Science Publishers, 1985:325-66.
2. Neurath AR, Kent SB, Strick N, Parker K. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell 1986;46:429-36.
3. Ashton-Rickardt PG, Murray K. Mutations that change the immunological subtype of hepatitis B virus surface antigen and distinguish between antigenic and immunogenic determination. J Med Virol 1989;29:204-14.
4. Ashton-Rickardt PG, Murray K. Mutants of the hepatitis B virus surface antigen that define some antigenically essential residues in the immunodominant a region. J Med Virol 1989;29:196-203.
5. Carman WF, Zanetti AR, Karayiannis P et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990;336:325-9.
6. Brown SE, Howard CR, Zuckerman AJ, Steward MW. Affinity of antibody responses in man to hepatitis B vaccine determined with synthetic peptides. Lancet 1984;11:184-7.
7. Howard CR, Stirk HJ, Brown SE et al. Towards the development of synthetic hepatitis B vaccine. In: Zuckerman AJ, ed. Viral Hepatitis and Liver Disease. New York: Alan R Liss, 1988:1094-101.
8. Chen Y-CJ, Delbrook K, Dealwis C et al. Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phage peptide library. Proc Natl Acad Sci USA 1996;93:1997-2001.
9. Qiu X, Schroeder P, Bridon D. Identification and characterization of a C(K/R)TC motif as a common epitope present in all subtypes of a hepatitis B surface antigen. J Immunol 1996;156:3350-6.
10. Magnius LO, Norder H. Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Intervirology 1995;38:24-34.
11. Wallace L, Carman WF. Surface gene variation of HBV: scientific and medical relevance. Viral Hepat Rev 1997;3:5-16.
12. Jazayeri SM, Basuni AA, Sran N et al. HBV core sequence:definition of genotype-specific variability and correlation with geographical origin. J Viral Hepat 2004;11:488-501.
13. Bancroft WH, Mundon FK, Russell PK. Detection of additional antigenic determinants of hepatitis B antigen. J Immunol 1972;109:842-8.
14. Courouce Pauty AM, Plancon A, Soulier JP. Distribution of HBsAg subtypes in the world. Vox Sang 1983;44:197-211.
15. Okamoto H, Omi S, Wang Y et al. The loss of subtypic determinants in alleles, d/y or w/r on hepatitis B surface antigen. Mol Immunol 1989;26:197-205.
16. Norder H, Couroucé A-M, Magnius LO. Molecular basis of hepatitis B virus serotype variations within the four major subtypes. J Gen Virol 1992;73:3141-5.
17. Wallace LA, Echevarria JE, Echevarria JM, Carman WF. Molecular characterisation of envelope antigenic variants of hepatitis B virus from Spain. J Infect Dis 1994;170:1300-3.
18. Jazayeri MS, Basuni AA, Cooksley G, Locarnini S, Carman WF. Hepatitis B virus genotypes, core gene variability and ethnicity in the Pacific region. J Hepatol 2004;41:139-46.
19. Basuni AA, Butterworth L, Cooksley G, Locarnini S, Carman WF. Prevalence of HBsAg mutants and impact of hepatitis B infant immunisation in four Pacific Island countries. Vaccine 2004;22:2791-9.
20. Carman WF, Korula J, Wallace L et al. Fulminant reactivation of hepatitis B due to envelope protein mutant of HBV that escaped detection by monoclonal HBsAg ELISA. Lancet 1995;345:1406-7.
21. Francois G, Kew M, Van Damme P, Mphahlele MJ, Meheus A. Mutant hepatitis B viruses: a matter of academic interest only or a problem with far-reaching implications? Vaccine 2001;19:3799-815.
22. Fujii H, Moriyama K, Sakamoto N et al. Gly 145 to Arg substitution in HBs antigen of immune escape mutant of hepatitis B virus. Biochem Biophys Res Commun 1992;184:1152-7.
23. Hsu HY, Chang MH, Ni YH, Lin HH, Wang SM, Chen DS. Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis. Hepatology 1997;26:786-91.
24. Zanetti AR, Tanzi E, Manzillo G et al. Hepatitis B variant in Europe [letter]. Lancet 1988;2:1132-3.
25. Zuckerman AJ, Harrison TJ, Oon CJ. Mutations in S region of hepatitis B virus. Lancet 1994;343:737-8.
26. Zuckerman JN, Zuckerman AJ. Mutations of the surface protein of hepatitis B virus. Antiviral Res 2003;60:75-8.
27. Devesa M, Rodriguez C, Leon G, Liprandi F, Pujol FH. Clade analysis and surface antigen polymorphism of hepatitis B virus American genotypes. J Med Virol 2004;72:377-84.
28. Harrison TJ, Hopes EA, Oon CJ et al. Independent emergence of a vaccine-induced escape mutant of hepatitis-B virus. J Hepatol 1991;13:S105-S107.
29. Hino K, Okuda M, Hashimoto O et al. Glycine-to-arginine substitution at codon 145 of HBsAg in two infants born to hepatitis B e antigen-positive carrier. Dig Dis Sci 1995;40:566-70.
30. Hou J, Wang Z, Cheng J et al. Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepatology 2001;34:1027-34.
31. Huang X, Lu D, Ji G et al. Hepatitis B virus (HBV) vaccineinduced escape mutants of HBV S gene among children from Qidong area, China. Virus Res 2004;99:63-8.
32. Okamoto H, Yano K, Nozaki Y et al. Mutations within the s gene of hepatitis-B virus transmitted from mothers to babies immunized with hepatitis-B immune globulin and vaccine. Pediatr Res 1992;32:264-8.
33. Oon C-J, Lim G-K, Ye Z et al. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine 1995;13:699-702.
34. Thakur V, Kazim SN, Guptan RC, Malhotra V, Sarin SK. Molecular epidemiology and transmission of hepatitis B virus in close family contacts of HBV-related chronic liver disease patients. J Med Virol 2003;70:520-8.
35. Oon CJ, Chen WN, Goo KS, Goh KT. Intra-familial evidence of horizontal transmission of hepatitis B virus surface antigen mutant G145R. J Infect 2000;41:260-4.
36. Chen WN, Oon CJ, Toh I. Altered antigenicities of hepatitisB virus surface antigen carrying mutations outside the common ‘a’ determinant. Am J Gastroenterol 2000;95:1098-9.
37. Alhababi F, Sallam TA, Tong CY. The significance of ‘anti-HBc only’ in the clinical virology laboratory. J Clin Virol 2003;27:162-9.
38. Carman WF, Owsianka A, Wallace LA, Dow BC, Mutimer DJ. Antigenic characterization of pre- and post-liver transplant hepatitis B surface antigen sequences from patients treated with hepatitis B immune globulin. J Hepatol 1999;31:195-201.
39. Protzer-Knolle U, Naumann U, Bartenschlager R et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998;27:254-63.
40. Seddigh-Tonekaboni S, Lim WL, Young B et al. Hepatitis B surface antigen variants in vaccinees, blood donors and an interferon- treated patient. J Viral Hepat 2001;8:154-8.
41. Karthigesu VD, Allison LMC, Fortuin M et al. A novel hepatitis B virus variant in the sera of immunized children. J Gen Virol 1994;75:443-8.
42. Carman WF, van Deursen FJ, Minims LT et al. The prevalence of surface antigen variants of hepatitis B virus in Papua New Guinea, South Africa and Sardinia. Hepatology 1997;26:1658-66.
43. Nainan OV, Khristova ML, Byun K et al. Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection. J Med Virol 2002;68:319-27.
44. Hino K, Katoh Y, Vardas E, Sim J, Okita K, Carman WF. The effect of introduction of universal childhood hepatitis B immunization in South Africa on the prevalence of serologically negative hepatitis B virus infection and the selection of immune escape variants. Vaccine 2001;19:3912-18.
45. Cooreman MP, Leroux-Roels G, Paulij WP. Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J Biomed Sci 2001;8:237-47.
46. Yamamoto K, Horita M, Tsuda F et al. Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. J Virol 1994;68:2671-6.
47. Mele A, Tancredi F, Romano L et al. Effectiveness of hepatitis B vaccination in babies born to hepatitis B surface antigen-positive mothers in Italy. J Infect Dis 2001;184:905-8.
48. Roznovsky L, Harrison TJ, Fang ZL et al. Unusual hepatitis B surface antigen variation in a child immunised against hepatitis B. J Med Virol 2000;61:11-14.
49. Wilson JN, Nokes DJ, Carman WF. Predictions of the emergence of vaccine-resistant hepatitis B in the Gambia using a mathematical model. Epidemiol Infect 2000;124:295-307.
50. Wilson JN, Nokes DJ, Carman WF. The predicted pattern of emergence of vaccine-resistant hepatitis B: a cause for concern? Vaccine 1999;17:973-8.
51. Wilson JN, Nokes DJ, Carman WF. Current status of HBV vaccine escape variants - a mathematical model of their epidemiology. J Viral Hepat 1998;5(Suppl. 2)):25-30.
52. Edmunds W, Medley G, Nokes D et al. The influence of age on the development of the hepatitis B carrier state. Proc R Soc Lond B Biol Sci 1993;253:197-201.
53. Anderson R, May R. Infectious Diseases of Humans: Dynamics and Control. Oxford: Oxford Science Publications, 1991.
54. Ogata N, Cote PJ, Zanetti AR et al. Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus. Hepatology 1999;30:779-86.
55. Chen WN, Oon CJ, Koh S. Horizontal transmission of a hepatitis B virus surface antigen mutant. J Clin Microbiol 2000;38:938-9.
56. Chen WN, Oon CJ, Lim GK. Frequent occurrence of hepatitis B virus surface antigen mutants in subtype adw in vaccinated Singapore infants. Vaccine 2001;20:639-40.
57. Terrault NA, Zhou S, McCory RW et al. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 1998;28:555-61.
58. Kao JH, Liu CJ, Chen DS. Hepatitis B viral genotypes and lamivudine resirtance. J Hepatol;36:303-304.
59. Zollner B, Schafer P, Feucht HH, Schroter M, Petersen J, Laufs R. Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy. J Med Virol 2001;65:659-63.
60. Zollner B, Petersen J, Schafer P et al. Subtype-dependent response of hepatitis B virus during the early phase of lamivudine treatment. Clin Infect Dis 2002;34:1273-7.
61. Chen WN, Oon CJ. Hepatitis B virus mutants: an overview. J Gastroenterol Hepatol 2002;17(Suppl.)):S497-S499.
62. Carman WF, Trautwein C, van Deursen FJ et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 1996;24:489-93.
63. Germer JJ, Charlton MR, Ishitani MB, Forehand CD, Patel R. Characterization of hepatitis B virus surface antigen and polymerase mutations in liver transplant recipients pre- and post-transplant. Am J Transplant 2003;3:743-53.
64. Ghany MG, Ayola B, Villamil FG et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998;27:213-22.
65. Ijaz S, Torre F, Tedder RS, Williams R, Naoumov NV. Novel immunoassay for the detection of hepatitis B surface ‘escape’ mutants and its application in liver transplant recipients. J Med Virol 2001;63:210-16.
66. Kim KH, Lee KH, Chang HY et al. Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy. J Med Virol 2003;71:367-75.
67. Santantonio T, Gunther S, Sterneck M et al. Liver graft infection by HBV S-gene mutants in transplant patients receiving longterm HBIg prophylaxis. Hepatogastroenterology 1999;46:1848-54.
68. Tillmann HL, Trautwein C, Bock T et al. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. Hepatology 1999;30:244-56.
69. McMahon G, Ehrlich PH, Moustafa ZA et al. Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant patients. Hepatology 1992;15:757-66.
70. Carman WF, McIntyre G, Klein H. Mutation of HBsAg in homograft recipients receiving hyperimmune globulin. J Hepatol 1992;16:S9.
71. Hawkins A, Gilson R, Gilbert N et al. Hepatitis B virus surface mutations associated with infection after liver transplantation. J Hepatol 1996;24:8-14.
72. McNair ANB, Viaggi P, Smith HM et al. Hepatitis B envelope protein mutants. Lancet 1995;346:318-19.
73. Owsianka A, Mutimer D, Dow B et al. Expression and antigenic analysis of HBsAg mutants associated with HBIG therapy after liver transplants. IX Triennial International Symposium on Viral Hepatitis and Liver Disease, Rome, Italy, 1996;1:Abstract D279: 348.
74. Ireland JH, O’Donnell B, Basuni AA et al. Reactivity of 13 in vitro expressed hepatitis B surface antigen variants in 7 commercial diagnostic assays. Hepatology 2000;31:1176-82.
75. Trautwein C, Schrem H, Tillmann HL et al. Hepatitis B virus mutations in the preS genome before and after liver transplantation. Hepatology 1996;24:482-8.
76. Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 2002;25:97-106.
77. Lok AS, Hussain M, Cursano C et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigennegative patients receiving lamivudine therapy. Hepatology 2000;32:1145-53.
78. Oon CJ, Chen WN, Lim N et al. Hepatitis B virus variants with lamivudine-related mutations in the DNA polymerase and the ‘a’ epitope of the surface antigen are sensitive to ganciclovir. Antiviral Res 1999;41:113-18.
79. Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000;31:1318-26.
80. Torresi J, Earnest-Silveira L, Deliyannis G et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002;293:305-13.
81. Bock CT, Tillmann HL, Torresi J et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002;122:264-73.
82. Cooreman MP, van Roosmalen MH, te Morsche R et al. Characterization of the reactivity pattern of murine monoclonal antibodies against wild-type hepatitis B surface antigen to G145R and other naturally occurring ‘a’ loop escape mutations. Hepatology 1999;30:1287-92.
83. Oon CJ, Chen WN, Goh KT et al. Molecular characterization of hepatitis B virus surface antigen mutants in Singapore patients with hepatocellular carcinoma and hepatitis B virus carriers negative for HBsAg but positive for anti-HBs and anti-HBc. J Gastroenterol Hepatol 2002;17(Suppl.)):S491-S496.
84. Singh H, Aggarwal R, Singh RL, Naik SR, Naik S. Frequency of infection by hepatitis B virus and its surface mutants in a northern Indian population. Indian J Gastroenterol 2003;22:132-7.
85. Weinberger KM, Bauer T, Bohm S, Jilg W. High genetic variability of the group-specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum. J Gen Virol 2000;81(Pt 5)):1165-74.
86. Weber B, Melchior W, Gehrke R, Doerr HW, Berger A, Rabenau H. Hepatitis B virus markers in anti-HBc only positive individuals. J Med Virol 2001;64:312-19.
87. Moriyama K, Ishibashi H, Kashiwagi S et al. Presence of HBV DNA and HBeAg in serum of an anti-HBs-positive individual [letter]. Gastroenterology 1989;97:1068-9.
88. Moriyama K, Nakajima E, Hohjoh H et al. Immunoselected hepatitis B virus mutant. Lancet 1991;337:125.
89. Carman WF, Dourakis S, Karayiannis P et al. Incidence of hepatitis B viraemia detected by PCR after successful therapy of chronic HBV carriers with interferon alpha. J Med Virol 1991;34:114-18.
90. Hou JL, Karayiannis P, Thomas HC et al. A unique insertion in the S gene of surface antigen negative HBV in Chinese carriers. Hepatology 1995;21:273-8.
91. Alexopoulou A, Baltayiannis G, Jammeh S, Waters J, Dourakis SP, Karayiannis P. Hepatitis B surface antigen variant with multiple mutations in the a determinant in an agammaglobulinaemic patient. J Clin Microbiol 2004;42:2861-5.
92. Coleman PF, Chen YC, Mushahwar IK. Immunoassay detection of hepatitis B surface antigen mutants. J Med Virol 1999;59:19-24.
93. Levicnik-Stezinar S. Hepatitis B surface antigen escape mutant in a first time blood donor potentially missed by a routine screening assay. Clin Lab 2004;50:49-51.
94. Moerman B, Moons V, Sommer H, Schmitt Y, Stetter M. Evaluation of sensitivity for wild type and mutant forms of hepatitis B surface antigen by four commercial HBsAg assays. Clin Lab 2004;50:159-62.
95. Weber B, Dengler T, Berger A, Doerr HW, Rabenau H. Evaluation of two new automated assays for hepatitis B virus surface antigen (HBsAg) detection: IMMULITE HBsAg and IMMULITE 2000 HBsAg. J Clin Microbiol 2003;41:135-43.
96. Zaaijer HL, Vrielink H, Koot M. Early detection of hepatitis B surface antigen and detection of HBsAg mutants: a comparison of five assays. Vox Sang 2001;81:219-21.
97. Mangold CMT, Unckell F, Werr M, Streeck RE. Secretion and antigenicity of hepatitis B virus small envelope proteins lacking cysteines in the major antigenic region. Virology 1995;211:535-43.
98. Seddigh-Tonekaboni S, Waters JA, Jeffers S et al. Effect of variation in the common ‘a’ determinant on the antigenicity of hepatitis B surface antigen. J Med Virol 2000;60:113-21.
99. Waters J, Kennedy M, Voet P. Loss of the common ‘a’ determinant of hepatitis B surface antigen by a vaccine induced escape mutant. J Clin Invest 1992;90:2543-7.
100. Jolivet-Reynaud C, Lesenechal M, O’Donnell B et al. Localization of hepatitis B surface antigen epitopes present on variants and specifically recognised by anti-hepatitis B surface antigen monoclonal antibodies. J Med Virol 2001;65:241-9.
101. Celis E, Ou D, Otvos L Jr. Recognition of hepatitis B surface antigen by human T lymphocytes. Proliferative and cytotoxic responses to a major antigenic determinant defined by synthetic peptides. J Immunol 1988;140:1808-15.
102. Honorati MC, Dolzani P, Mariani E et al. Epitope specificity of Th0/Th2 CD4+ T-lymphocyte clones induced by vaccination with rHBsAg vaccine. Gastroenterology 1997;112:2017-27.
103. Bauer T, Weinberger K, Jilg W. Variants of two major T cell epitopes within the hepatitis B surface antigen are not recognized by specific T helper cells of vaccinated individuals. Hepatology 2002;35:455-65.
104. Schirmbeck R, Dikopoulos N, Kwissa M et al. Breaking tolerance in hepatitis B surface antigen (HBsAg) transgenic mice by vaccination with cross-reactive, natural HBsAg variants. Eur J Immunol 2003;33:3342-52.
105. Schirmbeck R, Bohm W, Fissolo N, Melber K, Reimann J. Different immunogenicity of H-2 Kb-restricted epitopes in natural variants of the hepatitis B surface antigen. Eur J Immunol 2003;33:2429-38.
106. Fernholz D, Stemler M, Brunetto M et al. Replicating and virion secreting hepatitis B mutant virus unable to produce pre-S2 protein. J Hepatol 1991;13:S102-S104.
107. Huy TT, Ushijima H, Win KM et al. High prevalence of hepatitis B virus pre-S mutant in countries where it is endemic and its relationship with genotype and chronicity. J Clin Microbiol 2003;41:5449-55.
108. Lai ME, Melis A, Mazzoleni AP et al. Sequence analysis of hepatitis B virus genome of a new mutant of ayw subtype isolated in Sardinia. Nucleic Acids Res 1991;19:5078.
109. Santantonio T, Jung MC, Schneider R et al. Hepatitis-B virus genomes that cannot synthesize pre-S2 proteins occur frequently and as dominant virus populations in chronic carriers in Italy. Virology 1992;188:948-52.
110. Tai PC, Suk FM, Gerlich WH, Neurath AR, Shih C. Hypermodification and immune escape of an internally deleted middleenvelope (M) protein of frequent and predominant hepatitis B virus variants. Virology 2002;292:44-58.
111. Yeh CT, Chang MH, Lai HY, Chang ML, Chu CM, Liaw YF. Identification of a novel pre-S2 mutation in a subgroup of chronic carriers with spontaneous clearance of hepatitis B virus surface antigen. J Gastroenterol Hepatol 2003;18:1129-38.
112. Sugauchi F, Ohno T, Orito E et al. Influence of hepatitis B virus genotypes on the development of preS deletions and advanced liver disease. J Med Virol 2003;70:537-44.
113. Melegari M, Bruno S, Wands JR. Properties of hepatitis B virus pre-S1 deletion mutants. Virology 1994;199:292-300.
114. Xu Z, Yen TSB. Intracellular retention of surface protein by a hepatitis B virus mutant that releases virion particles. J Virol 1996;70:133-40.
115. Chisari FV, Filippi P, Buras J et al. Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice. Proc Natl Acad Sci USA 1987;84:6909-13.
116. Lenhoff RJ, Luscombe CA, Summers J. Competition in vivo between a cytopathic variant and a wild-type duck hepatitis B virus. Virology 1998;251:85-95.
117. Wang HC, Wu HC, Chen CF, Fausto N, Lei HY, Su IJ. Different types of ground glass hepatocytes in chronic hepatitis B virus infection contain specific pre-S mutants that may induce endoplasmic reticulum stress. Am J Pathol 2003;163:2441-9.
118. Summers J, Smith PM, Horwich AL. Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. J Virol 1990;64:2819-24.
119. Bartholomeusz A, Locarnini S. Hepatitis B virus mutants and fulminant hepatitis B: fitness plus phenotype. Hepatology 2001;34:432-5.
120. Hur GM, Lee YIK, Suh DJ et al. Gradual accumulation of mutations in precore core region of HBV in patients with chronic active hepatitis: implications of clustering changes in a small region of the HBV core region. J Med Virol 1996;48:38-46.
121. Fan YF, Lu CC, Chen WC et al. Prevalence and significance of hepatitis B virus (HBV) pre-S mutants in serum and liver at different replicative stages of chronic HBV infection. Hepatology 2001;33:277-86.